Stemline Therapeutics Inc. (NASDAQ:STML) traded down 2.7% during trading on Wednesday . The company traded as low as $9.61 and last traded at $9.81, with a volume of 70,302 shares traded. The stock had previously closed at $10.08.

A number of research analysts have recently issued reports on STML shares. Roth Capital reiterated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a research report on Thursday, June 9th. Jefferies Group reiterated a “buy” rating and set a $23.00 target price on shares of Stemline Therapeutics in a research report on Monday, June 6th. Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, June 7th. Finally, Zacks Investment Research lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Stemline Therapeutics has an average rating of “Buy” and an average target price of $19.31.

The firm’s 50-day moving average price is $8.15 and its 200 day moving average price is $6.73. The stock’s market cap is $181.99 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/stemline-therapeutics-inc-stml-shares-down-2-7.html

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Stemline Therapeutics had a negative return on equity of 44.59% and a negative net margin of 4,419.18%. Equities research analysts forecast that Stemline Therapeutics Inc. will post ($2.11) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the company. State Street Corp raised its stake in shares of Stemline Therapeutics by 3.3% in the first quarter. State Street Corp now owns 216,571 shares of the biopharmaceutical company’s stock valued at $1,008,000 after buying an additional 6,884 shares in the last quarter. Royce & Associates LP raised its stake in shares of Stemline Therapeutics by 9.4% in the first quarter. Royce & Associates LP now owns 174,179 shares of the biopharmaceutical company’s stock valued at $812,000 after buying an additional 15,000 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Stemline Therapeutics by 15.3% in the first quarter. Renaissance Technologies LLC now owns 79,100 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 10,500 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Stemline Therapeutics by 16.8% in the first quarter. Franklin Resources Inc. now owns 1,880,030 shares of the biopharmaceutical company’s stock valued at $8,761,000 after buying an additional 270,700 shares in the last quarter. Finally, BlackRock Fund Advisors raised its stake in shares of Stemline Therapeutics by 0.4% in the first quarter. BlackRock Fund Advisors now owns 406,268 shares of the biopharmaceutical company’s stock valued at $1,893,000 after buying an additional 1,724 shares in the last quarter. Institutional investors own 52.42% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.